199 completed, 12 terminated, 11 recruiting, 6 withdrawn. 236 Phase 3, 26 Phase 2.
Follow Attention Deficit and Disruptive Behavior Disorders: new trials by email Literature Review of Attention Deficit and Disruptive Behavior Disorders trials Research Report on Attention Deficit and Disruptive Behavior Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Approaches to Supporting Students With ADHD in Multi-Tiered Systems of Support Academic Competency Enhancement (ACE) classroom, School as Usual Classroom Supports - Attention Deficit Hyerpactivity Disorder | Phase 2 / Phase 3 | Not yet recruiting | Florida International University | 544 | 2027-01-01 | 2026-09-28 |
| A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation Centanafadine XR - Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 80 | 2026-09-01 | 2026-09-14 |
| An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD Solriamfetol - ADHD | Phase 3 | Enrolling by invitation | Axsome Therapeutics, Inc. | 300 | 2026-08-06 | 2026-10-13 |
| Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2) Solriamfetol Dose A, Solriamfetol Dose B, Placebo - ADHD | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 468 | 2026-07-06 | 2026-10-13 |
| A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD AK-D101, Placebo - Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder | Phase 3 | Not yet recruiting | Alvogen Korea | 156 | 2026-07-01 | 2026-07-02 |
| Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3) Solriamfetol Dose A, Solriamfetol Dose B, Placebo - ADHD | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 468 | 2026-06-25 | 2026-10-13 |
| A Long-term Trial of EB-1020 in Pediatric Patients With ADHD EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose - Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 180 | 2025-09-16 | 2025-12-23 |
| A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose, Placebo - Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 315 | 2025-09-03 | 2025-12-23 |
| A Long-term Trial of EB-1020 in Adult Patients With ADHD EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 180 | 2025-06-25 | 2026-10-23 |
| Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 630 | 2025-04-30 | 2026-10-23 |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety Centanafadine, Placebo - ADHD, Anxiety | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 315 | 2025-03-26 | 2026-05-06 |
| Virtual Reality Treatment for Emerging Adults With ADHD Meta Quest 3 VR Headset with noise cancelling headphones - Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Rutgers, The State University of New Jersey | 60 | 2024-09-20 | 2026-01-02 |
| Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules - Attention Deficit Hyperactivity Disorder | Phase 3 | Terminated | Ironshore Pharmaceuticals and Development, Inc | 26 | 2024-09-13 | 2025-11-06 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD AK0901 capsule, Placebo - ADHD | Phase 3 | Completed | Shanghai Ark Biopharmaceutical Co., Ltd. | 55 | 2024-05-28 | 2026-06-22 |
| EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders Placebo, Methylphenidate immediate release 25mg - Adult ADHD, Adult-onset ADHD With Mood Disorder | Phase 3 | Recruiting | University Hospital, Strasbourg, France | 80 | 2024-02-26 | 2026-08-21 |
| Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD NRCT-101SR - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Terminated | Neurocentria, Inc. | 95 | 2024-01-25 | 2026-01-15 |
| Benefits of ADHD Treatment in Detained People Concerta, Placebo - ADHD | Phase 3 | Recruiting | Stéphanie Baggio | 150 | 2024-01-01 | 2026-09-21 |
| Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) - ADHD, Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Cingulate Therapeutics | 103 | 2023-08-01 | 2026-01-22 |
| Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg - ADHD, ADHD - Combined Type | Phase 3 | Suspended | Cingulate Therapeutics | 45 | 2023-07-31 | 2026-05-05 |
| A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo - ADHD | Phase 3 | Completed | Axsome Therapeutics, Inc. | 516 | 2023-07-06 | 2026-02-10 |
Showing 20 of 236. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (228) · Spasm (10) · Oppositional Defiant Disorder (9) · Conduct Disorder (7) · Anxiety Disorders (5) · Impulsive Behavior (5) · Depression (4) · Mental Disorders (3) · Sleep Initiation and Maintenance Disorders (3) · Substance-Related Disorders (3) · Alcoholism (2) · Autistic Disorder (2) · Cocaine-Related Disorders (2) · Marijuana Abuse (2)
Neurodevelopmental Disorders (235) · Mental Disorders (233) · Nervous System Diseases (16) · Behavior (14) · Neurologic Manifestations (10) · Neuromuscular Manifestations (10) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Chemically-Induced Disorders (8) · Behavioral Symptoms (5) · Substance-Related Disorders (5) · Alcohol-Related Disorders (3) · Brain Diseases (3) · Central Nervous System Diseases (3)
Methylphenidate (46) · Atomoxetine Hydrochloride (28) · Lisdexamfetamine Dimesylate (14) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (10) · Guanfacine (8) · 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine (6) · Amphetamine (5) · Risperidone (5) · SLI381 (5) · Dexmethylphenidate Hydrochloride (4) · 5,10-dihydro-5-methylphenazine (3) · Capsules (3) · Fumigant 93 (3) · Modafinil (3) · SEP 225289 (3)
Shire (29) · Eli Lilly and Company (24) · Supernus Pharmaceuticals, Inc. (12) · Otsuka Pharmaceutical Development & Commercialization, Inc. (8) · Sumitomo Pharma America, Inc. (8) · Rhodes Pharmaceuticals, L.P. (7) · New York State Psychiatric Institute (5) · Novartis (5) · Noven Therapeutics (5) · University of Cincinnati (5) · Alza Corporation, DE, USA (4) · Axsome Therapeutics, Inc. (4) · Ironshore Pharmaceuticals and Development, Inc (4) · Otsuka Pharmaceutical Co., Ltd. (4) · Cephalon (3)
United States (137) · Germany (24) · Canada (19) · Belgium (14) · France (14) · United Kingdom (14) · Sweden (13) · Italy (12) · Spain (12) · Japan (10) · Netherlands (10) · South Korea (6) · Taiwan (6) · Norway (5) · Poland (5)
Ann Childress, MD (5) · Jonathan Rubin, MD (4) · Joseph Reiz (4) · Nobuhito Sanada (4) · Craig Surman, MD (2) · EunJin Park, MD (2) · Frances R Levin, MD (2)
PMID 25019647, PMID 33600233, PMID 33971070, PMID 34523063, PMID 36847750, PMID 35201607, PMID 36971690, PMID 37058600, PMID 38824626, PMID 41342306, PMID 11394191, PMID 20732631, PMID 20861587, PMID 21367347, PMID 21432592, PMID 21824454, PMID 25266438, PMID 27082828, PMID 34057707, PMID 34637343, PMID 34714112, PMID 41697570, PMID 42779129, PMID 11389303, PMID 11581440, PMID 12153826, PMID 12218423, PMID 12578439, PMID 16102908, PMID 16175106, PMID 16389216, PMID 16456216, PMID 16678648, PMID 17023867, PMID 17023868, PMID 17023869, PMID 17023870, PMID 17028508, PMID 17166338, PMID 17242628, PMID 17284136, PMID 17577466, PMID 18166547, PMID 18206857, PMID 18312050, PMID 18815438, PMID 19012813, PMID 19012818, PMID 19026251, PMID 19106767
2008 (2), 2009 (2), U10DA013732 (2), R01DA011444 (1), R01DA012234 (1), R01DA023652 (1), R01MH072263 (1), R01MH076244 (1), R01MH081854 (1), R01MH118313 (1), R03HD070621 (1), R29MH057093 (1), R61MH131632 (1), U01MH060642 (1), U01MH060833 (1)